Johnson & Johnson stock holds after updated 2026 guidance
Published on 08/10/2026 at 14:31 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Johnson & Johnson (US4781601046) stock reflects full-year 2026 guidance of $93.2 billion to $93.6 billion in sales and adjusted EPS of $10.80 to $10.90, while second-quarter 2026 sales reached $23.7 billion and adjusted EPS came in at $2.77. The company published those figures in its second-quarter 2026 update, giving the shares a fresh reference point for revenue, margin, and earnings power.
$23.7 billion in Q2
Second-quarter 2026 sales of $23.7 billion were reported alongside adjusted EPS of $2.77, and both figures matter because they set the tone for the back half of the year. The sales line also helps frame the company against its own 2026 outlook, which calls for full-year revenue of $93.2 billion to $93.6 billion.
That guidance implies a second-half run rate that remains central for investors watching whether the company can stay inside its earnings corridor of $10.80 to $10.90 per share. The combination of a quarterly sales base and a full-year earnings range is more useful than a headline price move alone.
2026 guidance stays firm
The 2026 outlook is the key comparison point: sales guidance of $93.2 billion to $93.6 billion and adjusted EPS guidance of $10.80 to $10.90 provide a narrow range for the rest of the year. By pairing those numbers with the second-quarter result, the company gives the market a simple framework for judging whether execution is on track.
For a large-cap healthcare name, that framework matters as much as any single product update because it ties operating performance to the balance sheet and the year-end earnings path. The market often re-prices Johnson & Johnson stock around whether reported quarterlies confirm or challenge that range.
Pharma drives the mix
The product mix remains anchored by pharmaceuticals and medical technology, with the former usually carrying the most weight in the earnings narrative. In this update, the most relevant product lens is whether drug revenue and procedure-related demand continue to support the 2026 sales target.
That matters because a company of this scale does not need one blockbuster quarter to impress; it needs a durable pattern that keeps annual guidance credible. The second-quarter sales number and the 2026 outlook together show that the company is still managing that task against a very large base.
Stock level and market value
As of 10 August 2026, Johnson & Johnson shares trade near a large-cap healthcare valuation backdrop rather than a pure momentum story. The stock price line is omitted here because the available evidence in this call is centered on reported earnings and guidance, not a dated exchange quote.
The market-capitalization and trading-venue line in the fact box provide the current market reference point, while the earnings figures above give the fundamental context that matters most for a company of this size. For investors, the latest quarter is useful because it combines a $23.7 billion sales base with a full-year guide that still points to $93.2 billion to $93.6 billion in revenue and $10.80 to $10.90 in adjusted EPS.
Johnson & Johnson product mix
Johnson & Johnson's product portfolio spans prescription medicines, medtech devices, and consumer-health assets sold under major healthcare brands. In practice, the market usually reads the company through pharmaceuticals and medtech first, because those businesses drive the bulk of reportable operating momentum.
Trading snapshot
Johnson & Johnson stock is best read through the latest earnings base rather than a single intraday quote. The company is valued as a major U.S. healthcare name on the New York Stock Exchange, and the numbers that matter most today are the $23.7 billion second-quarter sales figure and the 2026 guidance range for revenue and adjusted EPS.
Johnson & Johnson facts
- Company: Johnson & Johnson
- ISIN: US4781601046
- Ticker: NYSE: JNJ
- Trading venue: NYSE
- Market capitalization: USD 403 billion (as of 10 August 2026)
- Sector / Industry: Health Care / Pharmaceuticals, Biotechnology & Life Sciences
- Index membership: Dow Jones Industrial Average
